Revenue
2024
2025
Generate Biomedicines, Inc. (GENB)
Price—Loading quote
Net income
2024
2025
Free cash flow
2024
2025
Total cash / debt
CashTotal debt
2024
2025
Financial statements
| 2025 | 2024 | |
|---|---|---|
| Revenue | $31.9M | $20.5M |
| Research & development | $175.3M | — |
| Operating income | −$235.1M | −$196.9M |
| EBITDAderived | −$221.9M | −$181.6M |
| Net income | −$223.0M | −$181.4M |
| Diluted EPSper diluted share | -$7.57 | -$6.66 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Mar 4, 2026Form 4 | Nally MichaelChief Executive Officer | BuyCommon Stock | 20.0K | $12.00 | $240.0K | 572.7K |
| Mar 2, 2026Form 4 | Grous BethChief People Officer | BuyCommon Stock · indirect | 300 | $16.00 | $4.8K | 300 |
| Mar 2, 2026Form 4 | Silvers JasonPresident & CFO | BuyCommon Stock · indirect | 1.0K | $16.00 | $16.0K | 1.0K |
| Mar 2, 2026Form 4 | Silvers JasonPresident & CFO | BuyCommon Stock · indirect | 500 | $16.00 | $8.0K | 500 |
| Mar 2, 2026Form 4 | Silvers JasonPresident & CFO | BuyCommon Stock · indirect | 500 | $16.00 | $8.0K | 500 |